Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of maralixibat in adults aged 16 years and older with Alagille syndrome

Trial Profile

Study of maralixibat in adults aged 16 years and older with Alagille syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maralixibat (Primary)
  • Indications Alagille syndrome
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 26 Sep 2023 According to a Mirum Pharmaceuticals media release, data from this study will be presented at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting taking place October 4-7, 2023, in San Diego, California.
  • 07 Aug 2023 New trial record
  • 24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top